# Berkeley Lights

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/berkeley-lights

- Industry: Biotechnology
- Headquarters: Emeryville, US
- Website: www.berkeleylights.com
- Total disclosed funding: $126M
- Latest round: Series E (Oct 25, 2018)
- Investors on record: 11

## About

Based in the US, Berkeley Lights, Inc. specializes in advanced cellular analysis technologies, offering innovative solutions for researchers involved in single-cell functional analysis and therapeutic discovery.Berkeley Lights, Inc. was founded in 2011 in Emeryville, US, and operates in the field of cellular analysis technology. The company has raised a total of USD 258 mn, with its latest funding round being a Private Placement/Follow on in November 2020. Eric Hobbs serves as the CEO. Berkeley Lights has successfully completed 12 deals, with its most recent deal occurring on November 18, 2020.Berkeley Lights, Inc. specializes in cellular analysis technologies, particularly through its Beacon Discovery™ platform. This system facilitates live single-cell functional analysis, aiding in the discovery of therapeutic antibodies, T cell function interrogation, and cell line development. Its clientele includes academic institutions and biotech firms across North America, Europe, and Asia, offering critical tools for research and development in biopharmaceuticals.In the most recent fiscal year of 2022, Berkeley Lights, Inc. reported revenue of USD 78.60 mn and an EBITDA loss of USD 85.93 mn, generated primarily from the sales of its Beacon Discovery™ system and related services, which include both one-time purchases and subscription-based models for software and support.Berkeley Lights intends to utilize the funds from its latest funding round to enhance its research and development efforts and expand its product offerings, particularly in cell therapy. The company is focused on entering new markets for its advanced technologies, with specific plans for expansion in regions including Europe and Asia by 2025. Recent funding will also support these initiatives, ensuring continued innovation and market penetration.

## Funding rounds

- Series E, Oct 25, 2018, $51M — Hong Shan, WOORI Venture Partners, Atinum Investment, Varian Medical Systems, Inc., Black Diamond Ventures, Nikon Corporation, Cota Capital, Paxion Capital Partners, Celesta Capital, ShangBay Capital, AJS BioTree Healthcare Fund
- Series C, Apr 1, 2015, $56M — Hong Shan, Celesta Capital
- Series B, Jul 17, 2014, $19M — Celesta Capital

## Investors

- Celesta Capital (https://capitalatlas.ai/funds/celesta-capital) — Series B, Series C, Series E
- Hong Shan — Series C, Series E
- WOORI Venture Partners (https://capitalatlas.ai/funds/woori-venture-partners) — Series E
- Atinum Investment (https://capitalatlas.ai/funds/atinum-investment) — Series E
- Varian Medical Systems, Inc. — Series E
- Black Diamond Ventures (https://capitalatlas.ai/funds/black-diamond-ventures) — Series E
- Nikon Corporation — Series E
- Cota Capital (https://capitalatlas.ai/funds/cota-capital) — Series E
- Paxion Capital Partners (https://capitalatlas.ai/funds/paxion-capital-partners) — Series E
- ShangBay Capital (https://capitalatlas.ai/funds/shangbay-capital) — Series E
- AJS BioTree Healthcare Fund — Series E